PATENT CLAIM ANALYSIS

Application Number: 15773454
Application Type: Utility
Filing Date: 2018-05
Publication Date: 2018-12
Patent Classification: ["514", "364000"]

Abstract:
The present invention is directed to pharmaceutical compositions of an inhibitor of indoleamine 2,3-dioxygenase and are useful in the treatment of cancer and other disorders.

Claim (Index 2):
A method of treating cancer in a patient comprising administering to said patient a pharmaceutical composition comprising Compound 1, or a pharmaceutically acceptable salt thereof, and one or more excipients, in combination with a pharmaceutical composition comprising an inhibitor of an immune checkpoint molecule and one or more excipients, wherein the treating comprises a dosage regimen which attains at steady state:\n (3) a C max  from about 0.10 \u03bcM to about 10 \u03bcM, a C min  from about 0.01 \u03bcM to about 2.0 \u03bcM, a T max  of about 1 h to about 6 h and an AUC 0-\u03c4  from about 1 \u03bcM*h to about 50 \u03bcM*h; and \n (4) an I min  of about 50% or greater, or an I avg  of about 70% or greater.

Metadata:
- Claim Count in Document: 107.0
- Percentile: 93.0
- Lexical Diversity: 1.13043
- Patent Class: 514.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['15093420', '16061597', '13294711', '14661191', '14033117']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.768028174910541
- 35 USC 102 Novelty (BERT): 0.5395443656303364
- Combined Prediction Score: 0.7451797939825205
- Mean Citation Score: 260.49462800000003
- Max Citation Score: 267.73694
- Similarity Product: 160.61079623735904

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test